Mandate

Vinge has advised Lone Star Fund and Stark Group in connection with the sale of the Stark Group to CVC Capital Partners.

Headquartered in Denmark, STARK Group is a leading B2B distributor of heavy building materials for the construction industry in the Nordics and Germany, with a focus on serving professional craftsmen. The business partners with 10,000 suppliers to serve c. 235,000 customers from more than 400 locations in Denmark (incl. Greenland), Sweden, Norway, Finland, and Germany. The transaction is subject to customary conditions and approvals and is expected to close in Q2 2021.

Vinge’s team consisted of, among others, Jonas Bergström, Desirée Sjöblom, Vilhelm Rondahl and Amanda Steen (M&A), Michaela Cronemyr and Isabell Nielsen (Agreements), Frida Ställborn and Kristoffer Larson (Real Estate), Sara Strandberg and Caroline Edwall (Employment), Sofia Bergenstråhle (IP), Ludvig Wettergren and Jolinn Uhlin (Financial Arrangements), Fredrika Hjelmberg (IT), Nicklas Thorgerzon (GDPR), Lina Österberg (Permits), Tove Lövgren Frisk (Compliance) and the VDR assistant Carl Bruneheim.

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026